DDInter154 DDInter1789
Azelastine is a phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. It has a role as a H1-receptor antagonist, an anti-allergic agent, an anti-asthmatic drug, a bronchodilator agent, a platelet aggregation inhibitor and an EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor. It is a member of phthalazines, a tertiary amino compound and a member of monochlorobenzenes.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. Due to severe teratogenicity, pregnancy must be excluded before the start of treatment and patients must enrol in the THALIDOMID Risk Evaluation and Mitigation Strategy (REMS) program to ensure contraception adherence.
Azelastine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Thalidomide
Azelastine {u} (Compound) downregulates {v} (Gene) DNAJA3
DNAJA3 {u} (Gene) is downregulated by {v} (Compound) Thalidomide
Azelastine {u} (Compound) causes {v} (Side Effect) Hyperkinesia
Hyperkinesia {u} (Side Effect) is caused by {v} (Compound) Thalidomide
Azelastine {u} (Compound) resembles {v} (Compound) Loxapine
Loxapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Azelastine {u} (Compound) resembles {v} (Compound) Clozapine
Clozapine {u} may lead to a major life threatening interaction when taken with {v} Thalidomide
Azelastine {u} (Compound) binds {v} (Gene) CYP2E1
CYP2E1 {u} (Gene) is bound by {v} (Compound) Menadione
Menadione {u} (Compound) resembles {v} (Compound) Thalidomide
Azelastine {u} (Compound) binds {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) regulates {v} (Gene) GRB7
GRB7 {u} (Gene) is downregulated by {v} (Compound) Thalidomide
Azelastine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Clarithromycin
Clarithromycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Azelastine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Thioridazine
Thioridazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Azelastine {u} (Compound) downregulates {v} (Gene) DNAJA3
DNAJA3 {u} (Gene) is regulated by {v} (Gene) CYP3A5
CYP3A5 {u} (Gene) is bound by {v} (Compound) Thalidomide
Azelastine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Thalidomide (Compound)
Azelastine (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is downregulated by Thalidomide (Compound)
Azelastine (Compound) causes Hyperkinesia (Side Effect) and Hyperkinesia (Side Effect) is caused by Thalidomide (Compound)
Azelastine (Compound) resembles Loxapine (Compound) and Loxapine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Azelastine (Compound) resembles Clozapine (Compound) and Clozapine may lead to a major life threatening interaction when taken with Thalidomide
Azelastine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Menadione (Compound) and Menadione (Compound) resembles Thalidomide (Compound)
Azelastine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) regulates GRB7 (Gene) and GRB7 (Gene) is downregulated by Thalidomide (Compound)
Azelastine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Clarithromycin (Compound) and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Azelastine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Azelastine (Compound) downregulates DNAJA3 (Gene) and DNAJA3 (Gene) is regulated by CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)